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Abstract
Background: Brain metastases are common in clinical practice. Many clinical scales exist for predicting survival and
hence deciding on best treatment but none are individualised and none use quantitative imaging parameters. A
multicenter study was carried out to evaluate the prognostic utility of a simple diffusion weighted MRI parameter,
tumor apparent diffusion coefficient (ADC).
Methods: A retrospective analysis of imaging and clinical data was performed on a cohort of 223 adult patients
over a ten-year period 2002–2012 pooled from three institutions. All patients underwent surgical resection with
histologically confirmed brain metastases and received adjuvant whole brain radiotherapy and/or chemotherapy.
Survival was modelled using standard clinical variables and statistically compared with and without the addition of
tumor ADC.
Results: The median overall survival was 9.6 months (95% CI 7.5–11.7) for this cohort. Greater age (p = 0.002), worse
performance status (p < 0.0001) and uncontrolled extracranial disease (p < 0.0001) were all significantly associated with
shorter survival in univariate analysis. Adjuvant whole brain radiotherapy (p = 0.007) and higher tumor ADC (p < 0.001)
were associated with prolonged survival. Combining values of tumor ADC with conventional clinical scoring systems
such as the Graded Prognostic Assessment (GPA) score significantly improved the modelling of survival (e.g.
concordance increased from 0.5956 to 0.6277 with Akaike’s Information Criterion reduced from 1335 to 1324).
Conclusions: Combining advanced MRI readings such as tumor ADC with clinical scoring systems is a potentially simple
method for improving and individualising the estimation of survival in patients having surgery for brain metastases.
Keywords: Brain metastasis, Cerebral metastasis, Diffusion MRI, DWI, Biomarkers, Survival modelling, Personalised
medicine
Background
Brain metastases (BM) are an increasing clinical chal-
lenge causing significant morbidity and mortality [1].
Multiple treatments are available including neurosurgical
resection, radiotherapy, radiosurgery, chemotherapy and
immunotherapy. The variety of available treatments can
make it difficult to formulate a patient-specific treatment
plan. To help, simple prognostic models based on clin-
ical information were developed, including the Recursive
Partitioning Analysis (RPA) scale [2] and Graded Prog-
nostic Assessment (GPA) score [3]. Recent schemes have
added primary cancer (the disease-specific GPA [4]) and
biological information such as receptor pathway status
and biochemical parameters [5–8] but no study has
added advanced quantitative imaging measures to try
and improve these models.
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Although commonly used, the performance status -
which is the major factor in these scores - is subjective and
can vary between visits due to confounders such as cortico-
steroid use. There is a need for objective, non-invasive bio-
markers that reflect the intrinsic biologic behaviour of the
tumor. Diffusion weighted imaging (DWI) is a rapidly ob-
tained sequence in clinical practice and is an accepted part
of standard brain tumor imaging [9]. Single center studies
have identified apparent diffusion coefficient (ADC) values
within the BM as a particularly promising marker; tumor
ADC correlated with survival and recurrence after surgical
resection [10] and survival after radiosurgery [11], whilst
ADC changes at the tumor edge may indicate a more
locally aggressive phenotype [12].
Therefore, it is logical to add tumor ADC to traditional
clinical scores like RPA, GPA to determine whether this
improves the prediction of survival. This would be of im-
mense clinical value in helping to select the appropriate
treatments for the individual patient based on their prog-
nosis – personalised medicine – without the need for
further invasive tests or procedures. Also as a proof of
concept for applying an advanced MRI biomarker in this
additive way, we are perhaps opening up the possibility of
including it in future larger studies.
This study retrospectively pooled clinical and radio-
logical data of patients with BM from three institutions
and compared survival models using just the standard
clinical factors with those using standard clinical fac-
tors plus an imaging biomarker, the tumor ADC. This
allowed an evaluation of whether the imaging marker
could improve the prognostication of overall survival in
patients with surgically resected BM. In addition to
providing sufficient numbers for statistical analysis, the
collaborative nature of the project across three differ-
ent institutions will help in establishing the external
validity of the results, assess any differences in acquir-
ing the imaging marker between large centers and
identify obstacles that may hinder its implementation
in clinical practice.
Methods
Study design, setting and participants
This was a retrospective study of 223 adult patients with
resected BM from solid organ cancers across three spe-
cialist departments in Austria (Medical University of
Vienna, VIE, n = 30), the United States of America (Uni-
versity of Pennsylvania, PENN n = 100) and the United
Kingdom (Walton Centre Liverpool, LIV, n = 93) over a
10 year period 2002–2012. Patient demographics and rele-
vant clinical details about the studied population are listed
in Table 1. A retrospective study design was chosen as it
meant that patients with complete survival data and MRI
data were immediately available to test the hypothesis. All
cases in this time period who had undergone surgical
resection of a solitary BM (multiple metastases were in-
cluded only when there was a single dominant metastasis
being operated upon along with other smaller lesions,
reflecting the real life situation) were included. Exclusions
were any patient without a preoperative DWI study or
Table 1 Demographic and clinical summary (n = 223)
Factor Median IQ range
Age 59 years 52–67
Category Count
(% of total)
Gender Male 106 (48%)
Female 117 (52%)
KPS > 70 162 (73%)
< 70 61 (27%)





Unknown primary 2 (1%)
Other 37 (17%)
Status extracranial disease Complete response 36 (16%)
Partial response 4 (2%)
Stable disease 26 (12%)
Progressive disease 28 (13%)
No evidence of disease 41 (18%)
Synchronous 87 (39%)
Number of brain metastases 1 158 (71%)
2 30 (13%)
3 11 (5%)
> 3 24 (11%)
RPA Class I 62 (28%)
II 151 (68%)
III 10 (4%)
GPA score 0-1 26 (12%)
1.5 - 2 108 (48%)
2.5 - 3 53 (24%)
3.5 - 4 36 (16%)
DS-GPA score 0-1 29 (16%)
1.5 - 2 111 (60%)
2.5 - 3 36 (19%)






KPS Karnofsky performance status, RPA recursive partitioning analysis, GPA
graded prognostic assessment, DS-GPA disease specific GPA, WBRT whole
brain radiotherapy
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patients who had previous radiation therapy either local
or whole brain as this could have altered the diffusion
characteristics. Limiting the study to surgically resected
metastases meant that the diagnosis was certain (with
pathology being the gold standard), there was no variation
in treatment (standard of care was surgery then whole
brain radiotherapy (WBRT) and this study period predates
the use of cavity radiosurgery, immunotherapy, laser inter-
stitial therapy). The most widely used scores for predicting
survival in tumor boards, multidisciplinary team meetings
and clinics were calculated using the clinical information -
the GPA, disease-specific GPA and RPA score [2–4].
Imaging acquisition and analysis
As this was a pragmatic retrospective study, post-contrast
T1 and DWI sequences had already been obtained pre-
operatively as per each institution’s local protocol. For
PENN, DWI was acquired at 3Tesla using a single shot
spin-echo echo planar; TR/TE 5000/86ms, FOV 22 × 22
cm, 3mm slice thickness, 128 × 128 matrix, 30 diffusion di-
rections. For LIV: two sequences were used at 3Tesla, a
spin echo DwiSE sequence, TR/TE 2828/73ms, FOV
23x23cm, 4mm slice thickness, 128 × 128 matrix and 32
diffusion directions or DTI with TR/TE 8000/87.8ms, FOV
24x24cm, 4mm slice thickness, 128 × 128 matrix and 25 di-
rections. For VIE: DWI examinations were performed at
1.5Tesla and 3Tesla. Imaging parameters varied due to dif-
ferent scanners; slice thickness, range 3 - 6mm; FOV, range
128 × 128 – 384 × 384. Diffusion weighting was applied
with ‘b’ values of 0 and 1000 s/mm2 in all institutions.
Image processing has been described in previous studies
and used standard techniques, relying on the contrast-
enhanced T1-weighted scan for delineating the margins of
the BM. Mean tumor ADC was calculated from the con-
trast enhancing tumor avoiding cystic or haemorrhagic
areas. An example of one technique using circular regions
Fig. 1 Example of measurement of tumor ADC by manual placement of regions of interest A patient with a history of lung adenocarcinoma
presents with headache and focal neurological deficit. a. T1 weighted MRI with gadolinium demonstrates a left parietal lesion, which was
confirmed as a metastasis by pathology. b. ADC map is generated from DWI using post processing software and fused to the T1 post contrast
study. C and D are zoomed images of B as outlined in green. c. A region of interest is traced around the tumor border using the T1-weighted
post gadolinium scan and then applied to the ADC map. d. Regions of interest of an agreed size - here five circles of 50mm2 -are placed within
the tumor on the axial slice with the largest area, avoiding necrosis, haemorrhage or cyst, and the overall mean is calculated
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of interest (ROI) (each 50mm2) is illustrated in Fig. 1. ADC
readings were taken by a single radiology trained researcher
at each institution blind to the clinical outcomes although
we have previously demonstrated there is good intra and
inter-rater reliability for this type of measurement amongst
radiologists and trained researchers [13]. Only the largest,
resected BM was assessed for those with multiple lesions
(note that in general the cases with more than one metasta-
sis included a dominant lesion with only small additional
lesions).
Statistical methods
MRI data were processed at each individual institution,
then MRI results along with clinical data were anon-
ymized and statistical analysis performed at one institu-
tion by one statistics researcher with expertise in
survival analysis and modelling (DH at LIV). Overall sur-
vival (OS) from initial diagnosis of BM to death was cal-
culated, censored at the last recorded clinical contact. In
univariate analysis differences in OS were examined,
using log rank tests, based on each of the factors listed
in Table 1. Data were stratified by center to account for
potential confounding differences in treatment, MRI ac-
quisition parameters and follow up between institutions.
A Cox proportional hazards model was fitted for each of
GPA, RPA, WBRT and ADC separately and then all
combinations of these variables. The goal was to exam-
ine which model best described overall survival. In
multivariate analysis, the best fitting Cox proportional
hazards models were selected using variable reduction
by Akaike’s Information Criterion (AIC) [14], which is a
way of measuring concordance (how well the model fits
the data) whilst penalising for extra parameters. Specific-
ally, a low AIC value indicates a more accurate model.
Statistical analysis was performed using R version 3.21
(R Core Team, 2013).
Results
Clinical outcomes for this population
Median overall survival was 9.6 months (95% CI 7.7–11.7).
A total of 187 deaths were observed in our cohort (83.9%)
during a median follow up of 9.6 months (interquartile
range = 4.5 to 17.3months, minimum follow up = 7 days,
maximum follow up = 8 years). Greater age (hazard ratio
[HR] for death = 1.02, 95% CI 1.01–1.04, p = 0.002), worse
KPS (HR = 1.03, 95% CI 1.02–1.05, p < 0.0001) and uncon-
trolled extracranial disease (partial, progressive or syn-
chronous vs. complete response, HR = 2.44, 95% CI 1.47–
4.06, p < 0.0001) were all significantly associated with
shorter survival in univariate analysis stratified by institu-
tion. A likelihood ratio test from a univariate cox model
(stratified by institution) with number of BM as the inde-
pendent predictor did not show a significant relationship
between number of metastases and time to death (p =
0.156). A likelihood ratio test from a univariate cox model
(stratified by institution) with cancer type as the independ-
ent predictor did not show a significant relationship be-
tween cancer type and time to death (p = 0.0573). GPA (I
vs. II p = 0.02, I vs. III p = 0.001, I vs. IV 0.154) and RPA
(class I vs. II, p = 0.0016, I vs. III p = 0.02) categories were
significantly associated with differences in survival in
univariate analysis. Disease specific-GPA data was not
significant on non-stratified analysis (p = 0.114), there-
fore it was not considered further. Adjuvant WBRT
(bearing in mind this was a historical series) was ad-
ministered in 144/223 of patients (64.6%) and was asso-
ciated with significantly longer survival (p = 0.007)
when stratified by center; therefore, it was included in
the subsequent multivariate analyses.
Imaging biomarker and influence on clinical models:
The median tumor ADC value was 1.001 × 10− 3 mm2/s
(range 0.268–1.753). The mean tumor ADC was 1.025 ×
10− 3 mm2/s, standard deviation 0.269. The ADC values
varied with cancer type (ANOVA ADC x primary
cancer, p = 0.001). As seen in Fig. 2, with regards to the
common clinical question of “what is the likely pri-
mary?”, it was not possible to distinguish the most com-
mon brain-tropic cancers using tumor ADC: lung, breast
and melanoma (Tukey HSD statistic breast vs. lung = −
9.7, breast vs. melanoma = − 184.5, lung vs. melanoma =
194.2, p > 0.05 all comparisons). Tumor ADC was found
to be significantly correlated with survival when treated
as a continuous covariate (HR = 0.99, for a unit change
of 1 in ADC), with a higher tumor ADC correlating with
longer survival (p < 0.001). Also, each time ADC was
added to a model, it decreased AIC suggesting that it
improves the model fit. Each time ADC was added to a
model, the predictive ability improved as shown by the
improved concordance (Table 2). To further investigate
whether this improvement in the model was actually due
to the addition of ADC (and that ADC was not just a
surrogate for cancer type), data was re-analysed for only
lung cancer patients, given this was the most common
tumor type in our series (n = 115). For the lung cancer
cohort, the mean tumor ADC is 1.039 × 10− 3 mm2/s (SD
0.262) and the median is 1.025 × 10− 3 mm2/s (range
0.268–1.713). The same results were observed, with im-
proved fit each time ADC was added (Table 3).
Discussion
Summary
This multicentre retrospective study suggests that for a
specific population of surgically resected brain metastases,
an advanced quantitative MRI based biomarker – the
tumor ADC - improves the prediction of overall survival
when added to the standard, widely used clinical indexes
such as recursive partitioning analysis (RPA) and graded
prognostic assessment (GPA) score.
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What new information this adds to the field
In this study, we have demonstrated that even in a
multi-institutional series using standard of care clinical
MRI techniques, there is a significant association of
tumor ADC with length of survival after resection and
improvement of existing clinical scores for predicting
survival by incorporating tumor ADC values. Predicting
prognosis is critical in patients with BM, not only to
guide management discussions between clinicians and
patients, but also to stratify patients for randomised tri-
als. The ADC values from three international institutions
were similar in range and variance to the values reported
in the literature [12, 15, 16]. This cohort is representa-
tive of routine clinical practice with respect to demo-
graphics, proportion of primary cancer types and overall
survival [1, 17]. There was also a clear separation of
patient survival based on the standard RPA and GPA
indices, lending further validity to our patient cohort.
Finally the effect we observed persisted even when just
lung cancer cases were analysed, suggesting that the
tumor ADC is not simply a surrogate of primary.
Limitations
From a technical point of view, we selected tumor ADC,
since single center studies of BMs have previously shown
an association of higher tumor ADC with improved sur-
vival or delayed recurrence after surgery or radiosurgery
[10, 12, 15, 16, 18], and this measurement is simple to
obtain in clinical practice. It would have been better if
the MRI data could have been uploaded centrally and
then analysis of ADC maps performed centrally, perhaps
by two researchers with some reliability analysis. How-
ever, this is not what would happen in clinical practice if
this measurement were adopted and placing ROIs over
the tumor on clinical workstations is something radiolo-
gists could reasonably do in the existing clinical work-
flow without the need of specialised software. To
maximize the generalizability of our study results, real,
retrospective data obtained at different institutions in
different countries were utilized and as a result details
about tumor volume, location and size were not avail-
able to be analysed as confounders. In general, as these
were resected tumors they were all likely to be large or
else they would have had SRS and in accessible rather
than deep locations (again, that would likely have
favoured SRS). Tumor volume may affect ADC and this
is why the method explicitly uses multiple areas of read-
ing and avoids necrosis, which is likely to be more com-
mon and centrally located in larger tumors. For the
same reasons, retrospective information about adjuvant
Fig. 2 Tumor ADC of 223 brain metastases by primary cancer type. The ADC values varied with cancer type (ANOVA ADC x primary cancer, p =
0.001) but it was not possible to distinguish the most common brain-tropic cancers: lung, breast and melanoma (Tukey HSD statistic breast vs.
lung = − 9.7, breast vs. melanoma = − 184.5, lung vs. melanoma = 194.2, p > 0.05 all comparisons). CUP = cancer of unknown primary. Only 7 renal
cell carcinoma cases were included so the higher tumor ADC in this group leading to the overall ANOVA result may be a sampling effect. Primary
cancer itself was not associated with overall survival in this series (see Results)
Table 2 Comparison of models for predicting overall survival in
brain metastases
Model AIC Concordance R2
Graded Prognostic Assessment (GPA) 1335.30 0.5956 0.1058
Recursive Partitioning Analysis (RPA) 1328.94 0.5999 0.1232
GPA + Tumor ADC 1324.48 0.6277 0.1558
RPA + Tumor ADC 1321.84 0.6240 0.1582
GPA +WBRT + Tumor ADC 1292.37 0.6545 0.1834
RPA +WBRT + Tumor ADC 1290.61 0.6662 0.1825
WBRT received adjuvant whole brain radiotherapy
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chemotherapy regimes were not available universally, al-
though whole brain radiation was documented and ana-
lysed. Chemotherapy in general is poorly effective against
BM although it may have affected overall survival which
reflects systemic disease. Extracranial disease control was
able to be analysed as it is a potential important con-
founder, and since this was a historical series, transforma-
tive treatments like immunotherapy which would
certainly have had a huge impact on overall survival - e.g.
for melanoma cases - were not in use. Primary cancer type
did not seem to influence survival in this cohort therefore
differences in treatment of the different primary cancers
(e.g. radioresistant vs. radiosensitive types or targeted
agents) did not seem be a confounder.
Biological significance and future directions
Although in stroke cases ADC has been shown to vary
with MRI coils, vendors and field strength [19] DWI data
appears to be comparable across vendors and institutions
[20, 21]. Practical measures such as using multiple readers,
standard derivations of measures and even cloud based
post-processing platforms for central processing of raw
data are all likely to minimise variation in future studies.
Nonetheless, even the current, widely used GPA and RPA
scales can suffer from inter-observer variability, such as
the subjective nature in which KPS is determined. Tumor
ADC is widely studied in other solid organ cancers as a
biomarker of survival [22] although paired values for pri-
mary and BM have not been reported, it would be inter-
esting to determine which influence overall survival more.
High tumor ADC has been correlated with lower tumor
cellularity [16], reduced extracellular matrix density [10]
and greater degree of tumor differentiation [12] in BM
and any of these could reasonably be surrogates of
improved survival. We do not suggest that quantitative
imaging biomarkers alone will replace the traditional clin-
ical factors that have demonstrated utility across large
numbers of patients over many years and changes in treat-
ment modalities. Rather, we propose that quantitative
imaging biomarkers be added to these clinical indices
towards improving and personalising prognostication.
Finally, the treatment paradigms in BM are currently
undergoing great change with neo-adjuvant and adjuvant
cavity SRS, immunotherapy and prophylactic chemother-
apy for asymptomatic micrometasteses all being reported.
This may make clinical models predicting prognosis obso-
lete. The solutions will be to re- apply these models to
each new cohort (e.g. does pre-op tumor ADC improve
survival modelling for surgery + cavity SRS patients too?),
which is exactly how they were refined and developed
originally and to embrace the opportunity to incorporate
these individualised, non-invasive biomarkers provided by
advanced MRI techniques (e.g. by testing MRI features
as a measure of immunotherapy response as has been
tried recently with post contrast features in a radiomics
approach [23]).
Conclusions
We have demonstrated that diagnostic MRI scans includ-
ing DWI sequences contain significant biological informa-
tion which can be incorporated with standard clinical
parameters to improve the prediction of overall survival in
patients with surgically resected BM and better inform
clinical decision making.
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